MET and neoplasm: Furthermore, Wang et al. (41) developed a magnetically driven hydrogel microrobot platform to enable targeted co-delivery of the MET inhibitor SCR1481B1 and the VEGFR inhibitor anlotinib, enhancing synergistic cytotoxicity within the tumour microenvironment.